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Simulated Prosthesis Overlay for Patient-Speciﬁc Planning
of Transcatheter Aortic Valve Implantation Procedures
Simon H. Su¨ndermann, MD,* Michael Gessat, PhD,Þ Willibald Maier, MD, PhD,þ Jo¨rg Kempfert, MD,*
Thomas Frauenfelder, MD, PhD,§ Thi D. L. Nguyen, MD,§ Francesco Maisano, MD,||
and Volkmar Falk, MD, PhD*
Objective: We tested the hypothesis that simulated three-dimensional
prosthesis overlay procedure planning may support valve selection in
transcatheter aortic valve implantation (TAVI) procedures.
Methods: Preoperative multidimensional computed tomography
(MDCT) data sets from 81 consecutive TAVI patients were included in
the study. A planning tool was developed, which semiautomatically
creates a three-dimensional model of the aortic root from these data.
Three-dimensional templates of the commonly used TAVI implants
are spatially registered with the patient data and presented as graphic
overlay. Fourteen physicians used the tool to perform retrospective
planning of TAVI procedures. Results of prosthesis sizing were
compared with the prosthesis size used in the actually performed
procedure, and the patients were accordingly divided into three
groups: those with equal size (concordance with retrospective plan-
ning), oversizing (retrospective planning of a smaller prosthesis), and
undersizing (retrospective planning of a larger prosthesis).
Results: In the oversizing group, 85% of the patients had new
pacemaker implantation. In the undersizing group, in 66%, at least
mild paravalvular leakage was observed (greater than grade 1 in one
third of the cases). In 46% of the patients in the equal-size group,
neither of these complications was observed.
Conclusions: Three-dimensional prosthesis overlay in MDCT-derived
patient data for patient-speciﬁc planning of TAVI procedures is feasible.
It may improve valve selection compared with two-dimensional MDCT
planning and thus yield better outcomes.
Key Words: Heart valve, transapical approach, Computed
tomography imaging, 3D modeling, Transcatheter aortic
valve replacement.
(Innovations 2015;10:314Y322)
Transcatheter aortic valve implantation (TAVI) has evolvedinto a routine procedure for treating aortic valve stenosis in
high-risk patients.1 Multidimensional computed tomography
(MDCT) images are used for the visualization and measure-
ment of aortic root landmarks and distances.2,3 Despite careful
planning, paravalvular leakage4 and atrioventricular block5
remain the most frequent complications after TAVI. In this
study, a newly developed prototype planning software was
used.6,7 With this software, three-dimensional (3D) templates
of the CoreValve [Medtronic, Inc, Minneapolis, MN USA
(CoreValve)] and SAPIEN [Edwards Lifesciences, Inc, Irvine,
CA USA (SAPIEN)] prostheses can be virtually implanted in
MDCT-derived 3D aortic root models in addition to the regular
two-dimensional (2D) visualization. We hypothesize that the
use of these 3D TAVI prosthesis templates might improve the
planning of TAVI procedures.
METHODS
Preoperative computed tomographic (CT) angiographies
of 81 patients were used to acquire retrospective planning data
with the 3D-template tool by 14 clinicians (8 surgeons, 3
cardiologists, 2 radiologists, 1 anesthesiologist) who partici-
pated in the study as active participants. The local authorities
approved the study (KEK-ZH No. 2011Y0393). Because of its
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retrospective character, written informed consent from the
patients was not required, but the anonymization of patient data
was handled very strictly.
End points were relevant paravalvular aortic insufﬁ-
ciency (AI, grade 9 1+) and new pacemaker (PM) implantation.
Postoperative transesophageal and transthoracic echocardiog-
raphy reports and images from up to 3 months after inter-
vention were used to classify paravalvular AI from 0 (no
paravalvular AI) to grade 4 (severe paravalvular AI). In-
dications for perioperative new PM implantation were new
conduction system disorders such as third-degree or advanced
second-degree atrioventricular block not expected to resolve or
the presence of sinus node dysfunction and documented
symptomatic bradycardia in accordance with the American
College of Cardiology/American Heart Association/Heart
Rhythm Society recommendations for device-based therapy of
cardiac rhythm abnormalities.8
Risk factors for the development of AI (ie, New York
Heart Association class IV, absence of previous valve surgery,
asymmetric calciﬁcation,9 and oval annulus shape4) and new
PM implantation [ie, porcelain aorta, absence of previous aortic
valve surgery,10 and preoperative right bundle branch block
(RBBB)11] were assessed from themedical reports of the patients.
Imaging and Preprocedural Planning
All preoperative CT examinations were performed using
a second-generation, 128-slice DSCT system (Somatom Def-
inition Flash, Siemens Healthcare, Forchheim, Germany).
Iopromide 40 mL (Ultravist 300, 300 mg/mL; Bayer Schering
Pharma, Berlin, Germany) was injected at a ﬂow rate of 4 mL/s,
followed by 40-mL bolus of saline solution at the same ﬂow rate.
Bolus tracking in the ascending aortawas performed with a signal
attenuation threshold of 100 Hounsﬁeld units. A craniocaudal
scan direction was chosen in all protocols. The scan ranged
from the apex of the lung to the symphysis. The CT scan was
started automatically based on the previous 10 heartbeats to
reach the 60% R-R interval at the level of the valve.
Before the actual implantations, which were performed
between January 2010 and January 2012, prosthesis selection was
based on imaging as follows: the center line of the aortic root and
the ascending aortawas drawn semiautomatically using dedicated
software (3mensio benzslicer 4.3, Bilthoven, the Netherlands).
The aortic annulus was deﬁned by marking the three insertion
points of each leaﬂet at the nadir of the sinus. The largest and
shortest diameters and the circumference were measured.
Asymmetric calciﬁcation was regarded as present when
the leaﬂet and annulus of one sinus visually had at least the
same level of calciﬁcation as the two other sinuses together. The
annulus shape was classiﬁed as oval when the longer diameter
was equal to or greater than 120% of the shorter diameter.
Study-Speciﬁc Retrospective Planning With 3D
TAVI Templates
Planning Software
The prototype planning software was developed as de-
scribed previously.6,7We used the open-source software libraries
VTK and DCMTK and the open-source framework OpenMAF
2.0 as the basis for development. The planning workﬂow im-
plemented in this tool is depicted in Figure 1 and can be seen in
video 1, SDC, http://links.lww.com/INNOV/A60.
FIGURE 1. Workﬂow of 3D template based TAVI planning as used in the study. 3D, three dimensional; TAVI, transcatheter aortic
valve implantation.
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Data Import
Patient MDCT images and segmentations of the aortic
root, aortic valve, and left ventricle are imported from a local
storage or via the network from a PACS [picture archiving and
communication system] server.
Three-dimensional Landmark Localization
A3Dvisualization of the segmentations is presented to the
user who is prompted to localize eight landmarks on the seg-
mented surfaces: the three nadirs of the aortic valve sinus, the three
aortic valve commissures, and the two coronary ostia (00:00Y00:30
in the video, SDC, http://links.lww.com/INNOV/A60).
Automatic Plane Computation
Three planes are computed from these landmarks: the
basal or annular plane (yellow), which is deﬁned by the three
nadirs of the sinus; the commissural plane (blue) through the
three commissures; and the coronary plane (red), which is
parallel to the sinus plane and runs through the lower of the
two ostia (right lower window in the video from 00:30, SDC,
http://links.lww.com/INNOV/A60).
Two-dimensional Landmark Reﬁnement
The 3D visualization allows for quick orientation and
identiﬁcation of the landmarks (and thereby deﬁnition of the
three planes), but because of limitations in the segmentation
accuracy, the selected landmarks are not 100% accurate. To
improve the accuracy, the user is prompted to check and reﬁne
each landmark in a 2D cross-sectional visualization of the CT
images. The system automatically offers three different triplanar
sections showing all three commissures, all three sinus, or both
coronary landmarks, respectively. At the press of a button the
user can switch between these three views, reﬁne the landmark
positions, and thereby update the plane deﬁnitions (00:31Y00:57
in the video, SCD, http://links.lww.com/INNOV/A60).
Annulus Sizing
After reﬁnement and conﬁrmation of the landmarks, a
circle of best ﬁt through the aortic annulus is computed
according to the sinus landmarks and visualized in the cross-
sectional view. The user may adjust the radius and the center
of this circle manually (00:58Y01:15 in the video, SDC,
http://links.lww.com/INNOV/A60).
FIGURE 2. Automatically registered 3D templates representing the SAPIEN valve (Edwards Lifesciences) (left side) and CoreValve
(Medtronic) (right side) prostheses. 3D, three dimensional.
FIGURE 3. Measurement of the implantation depth of the CoreValve (Medtronic) prosthesis (left side) and the SAPIEN Valve
(Edwards Lifesciences) prosthesis. The formula to calculate the part of the SAPIEN prosthesis below the annulus is as described by
Nijhoff et al13: [(D / C) + (B / A)] / 2  100].
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Automatic Implant Template Registration
Once the annular ring is accepted, the system automatically
registers 3D templates representing the SAPIEN valve (Edwards
Lifesciences, Inc, Irvine, CA USA) and CoreValve (Medtronic,
Inc, Minneapolis, MNUSA) prostheses with the annulus (Fig. 2).
The prosthesis templates are positioned perpendicular to the sinus
plane at the center of the circle that was deﬁned to mark the
annulus. Implantation depth is deﬁned such that the nadirs of the
implants’ leaﬂets are at the level of the natural nadirs of the aortic
valve sinus. In the case of the SAPIEN prostheses, the vertical
distance to the coronary ostia is also considered hereby. A 1-mm
safety margin is maintained between the distal rim of the
prostheses and the lower ostium (01:16Y01:45 in the video,
SDC, http://links.lww.com/INNOV/A60).
Implant Selection
The user may adjust the orientation and position in three
dimensions of each template and choose the best-ﬁtting tem-
plate. Two-dimensional and 3D visual overlays of the CT im-
ages, anatomical models, and 3D templates were provided to
allow for a visual assessment of the suitability of each of the
available implant prostheses. The main criterion for selection
was not a numerical (diameter) but a visual selection of the
optimal match of valve size and type (01:46Y3:21 in the video,
SDC, http://links.lww.com/INNOV/A60).
The resulting selection, the ﬁnal landmark positions, and
the spatial registration that determines the orientation and
TABLE 1. Baseline Characteristics
Total Equal Size Undersizing Oversizing P
n 81 54 20 7
Age, mean (SD), y 84 (6) 83 (6) 85 (4) 84 (4) 0.4
Female sex, n (%) 44 (54.3) 32 (59) 9 (45) 3 (42) 0.5
Logistic EuroSCORE, mean (SD), % 21.3 (11.8) 20.2 (9.1) 25.1 (17.9) 19.3 (7.3) 0.3
Left ventricular ejection fraction, mean (SD), % 55.1 (12.7) 56.9 (11.7) 51.8 (14.8) 50 (12.8) 0.2
NYHA class (III-IV), n (%) 59 (73) 36 (67) 18 (90) 5 (71) 0.1
Previous aortic valve surgery, n (%) 3 (3.7) 3 (5.6) 0 0 0.5
Previous CABG, n (%) 18 (22.2) 15 (28) 3 (15) 0 0.2
Coronary heart disease, n (%) 45 (55.6) 28 (52) 12 (60) 5 (71.4) 0.6
Peripheral vascular disease, n (%) 24 (29.6) 15 (27.8) 8 (40) 1 (14.3) 0.4
Previous myocardial infarction, n (%) 8 (9.9) 6 (11.1) 1 (5) 1 (14.3) 0.7
Previous PCI, n (%) 29 (35.8) 17 (31.5) 9 (45) 3 (42.9) 0.5
Previous stroke/TIA, n (%) 9 (11.1) 5 (9.3) 3 (15) 1 (14.3) 0.8
Renal failure, n (%) 34 (42) 22 (40.7) 9 (45) 3 (42.9) 0.9
COPD, n (%) 6 (7.4) 3 (5.6) 2 (10) 1 (14.3) 0.6
Pulmonary hypertension, n (%) 3 (3.7) 3 (5.6) 0 0 0.5
AF, n (%) 18 (22.2) 8 (14.8) 7 (35) 3 (42.9) 0.1
RBBB 8 (9.9) 5 (9.3) 1 (5) 2 (28.6) 0.2
LBBB 7 (8.6) 11 (6.1) 3 (15) 1 (14.3) 0.3
Peak aortic valve gradient, mean (SD), mm Hg 72.8 (22,8) 74.5 (21) 70.8 (26.8) 63.8 (27.4) 0.6
Mean aortic valve gradient, mean (SD), mm Hg 44.9 (14.6) 45.8 (13.2) 44.5 (18.2) 39.6 (15) 0.6
AVA, mean (SD), cm2 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.8 (0.3 0.3
Oval annulus 47 (58) 33 (61.1) 10 (50) 4 (57.1) 0.6
Asymmetric calciﬁcation 24 (30) 15 (27.8) 4 (20) 5 (71.4) G0.05
Porcelain aorta 3 (3.7) 3 (5.6) 0 0 0.5
AF, atrial ﬁbrillation; AVA, aortic valve area; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; LBBB, left bundle branch block; NYHA, New
York Heart Association; PCI, percutaneous coronary intervention; RBBB, right bundle branch block; TIA, transient ischemic attack.
TABLE 2. Procedural Details; SAPIEN: SAPIEN (32 Patients)
and SAPIEN XT (14 Patients)
Total Undersizing Oversizing P
n 81 20 7 V
CoreValve implantation, n (%)
23 mm 1 (1) 1 (5) 0 V
26 mm 13 (16) 1 (5) 0 V
29 mm 20 (25) 6 (30) 5 (71) V
31 mm 1 (1) 0 0 V
SAPIEN implantation, n (%)
23 mm 20 (25) 5 (25) 0 V
26 mm 21 (26) 7 (35) 1 (14) V
29 mm 5 (6) 0 1 (14) V
Transapical access, n (%) 10 (12) 0 0 V
Postdilatation, n (%) 9 (11) 5 (25) 0 0.3
Implantation depth CoreValve,
mean (SD), mm
12.2 (5.3) 12.6 (4.6) 10.4 (5.4) 0.5
Implantation depth SAPIEN,
mean (SD), % of stent height
7.9 (11.5) 9 (10) j10 (16) 0.3
Annulus rupture, n (%) 0 0 0 V
Coronary obstruction, n (%) 0 0 0 V
Peri-interventional MI, n (%) 0 0 0 V
Access site complications, n (%) 4 (5) 2 (10) 0 1
Other complications, n (%) 7 (9) 1 (5) 1 (14) 1
MI, myocardial infarction.
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position of the selected valve template in relation to the co-
ordinate system of the CT image are stored to a local hard drive
or a PACS server via the network.
Each case was planned by three participants. The assign-
ment of patients to participants was based on a semirandomized
scheme, which ensured that the distribution of complications
in each participant’s data set matched the distribution in the
complete data set. The participants had to choose the optimal
size of the CoreValve and of the SAPIEN valve for each patient.
Figure 2 shows the virtually implanted prostheses. Where the
three observers arrived at differing results for the same patient,
these results were aggregated based on a majority vote.
For each patient, the valve size selected was compared
with that of the actually implanted valve. The patients were
divided into three groups. Those for whom retrospective plan-
ning proposed a prosthesis smaller than actually implanted were
labeled the ‘‘oversizing’’ group. Those where retrospectively a
larger prosthesis was planned than actually implanted were the
‘‘undersizing’’ group. All other patients had equal sizing.
The study participants did not have access to the outcome
data and did not know before or during the retrospective plan-
ning process which valve type had been implanted.
The time for the whole planning process was measured,
starting with the placement of the ﬁrst landmark at the segmented
aorta and ﬁnishing at the ﬁnal decision on prosthesis size.
Postinterventional Evaluation of Depth of
Prosthesis Implantation
Deep implantation of the CoreValve prosthesis is a risk
factor for permanent PM implantation after the intervention.12
Therefore, the depth of implantation was assessed from the
intraoperative angiography of the ﬁnal implant position in the
implant projection in left anterior oblique view.
The distance from the annulus to the lowest point of
the stent was measured at both margins of the Medtronic
CoreValve Revalving System (CoreValve) prosthesis from the
nadir of the noncoronary sinus and the left coronary sinus, and
the mean implantation depth was calculated. The height of a
stent cell (8 mm) was taken as the reference structure to conﬁrm
the accuracy of the measurements.
For the SAPIEN prostheses, the part of the stent below
the annulus was assessed as described by Nijhoff et al.13 The
measurements were performed using Synedra software (ver-
sion 3.3.0.12; Synedra Information Technologies GmbH,
Innsbruck, Austria). Exemplary images of the measurement for
both prostheses are shown in Figure 3.
Statistics
Continuous variables were calculated as means with SD.
Differences in the means of continuous variables were calculated
by Student t test or one-way analysis of variance. For static vari-
ables, W2 test was used to compare the groups. Logistic regression
was used to calculate the association of risk factors and new PM
implantation and the development of signiﬁcant paravalvular in-
sufﬁciency. Multivariable logistic regression modeling was
performed to determine the independent predictors of new PM
implantation using purposeful selection of covariates. Variables
associated at univariate analysis with new PM implantation
(all with P G 0.1) as well as those judged to be of clinical im-
portance from previously published literature were eligible for
inclusion in the multivariable model-building process. For
paravalvular leakage, no association with any of the variables was
found in the univariate analysis. Therefore, no multivariate anal-
ysis was performed. A P value of less than 0.05 was considered
signiﬁcant. Data analysis was performed using IBM SPSS Sta-
tistics, version 22.0 (IBM Corporation, Armonk, NY USA).
RESULTS
Baseline Characteristics and Risk Factors
Baseline characteristics are summarized in Table 1. The
number of patients who had coronary artery bypass grafting in
their history was higher in the undersizing group (15% vs 0%),
more patients had peripheral vascular disease in the under-
sizing group (40% vs 14%), previous myocardial infarction
was more common in the oversizing group (14% vs 5%), and
more patients showed RBBB before implantation RBBB (29%
vs 5%) and asymmetric calciﬁcation (71% vs 20%) in the
oversizing group. No relevant differences were seen for the
other parameters.
Procedural Details
Thirty-ﬁve patients had received a CoreValve, and 46
patients had received a SAPIEN (32 patients SAPIEN, 14
patients SAPIEN XT) prosthesis (Table 2). Implantations were
mainly performed by transfemoral access (87.7%). None of the
patients experienced coronary obstruction or annulus rupture
during the intervention or showed signs of peri-interventional
myocardial infarction. Four patients had inguinal vascular
access site complications, and one patient from the undersized
group had a prosthesis dislocation, which ended in hemo-
dynamic instability and ﬁnally in the death of the patient.
Four patients had prosthesis embolization (one patient with
CoreValve implantation from the equal-size group; one patient
with CoreValve implantation from the oversizing group; one
patient from the SAPIEN group, who primarily had CoreValve
implantation, that embolized; and one patient form the equal-size
TABLE 3. Procedural Outcome
Total Undersizing Oversizing P
n 81 20 7
Paravalvular leak
(at least moderate), n (%)
10 (11) 7 (35) 0 0.1
SAPIEN 3 (4) 2 (10) 0
CoreValve 7 (9) 5 (25) 0
Paravalvular leak
(at least mild), n (%)
45 (56) 17 (85) 4 (57) 0.3
New PM implantation, n (%) 14 (17) 2 (10) 6 (85) 0.001
SAPIEN 5 (6) 1 (5) 2 (29)
CoreValve 9 (11) 1 (5) 4 (57)
Stroke, n (%) 0 0 0 V
30-d mortality, n (%) (n = 81) 4 (4.9) 3 (15) 0 0.5
6-mo mortality, n (%) (n = 63) 6 (7.3) 4 (20) 1 (14.3) 0.5
1-y mortality, n (%) (n = 51) 7 (8.5) 5 (25) 1 (14.3) 0.3
2-y mortality, n (%) (n = 21) 7 (8.5) 5 (25) 1 (14.3) 0.3
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SAPIENgroup) during the implantation; all valveswere replaced
during the same intervention. One of these patients died 2 days
after the event. Another patient had right ventricular perforation,
probably caused by the temporary PM probe; sternotomy and
suturing of the rupture site were necessary. All other implanta-
tions were uneventful.
The mean (SD) implantation depth of the CoreValve
prostheses was 12.2 (5.3) mm [12.6 (4.6) vs 10.4 (5.4) mm for
the undersizing vs the oversizing group, P = 0.5]. At the
noncoronary sinus, the mean (SD) implantation depth was 12.4
(5.5) mm [11.7 (4.1) vs 10.7 (5) mm for the undersizing group vs
the oversizing group, P = 0.7]. The mean (SD) implantation depth
at the left coronary sinuswas11.9 (5.7)mm[13.6 (5.3) vs11.8 (5.8)
mm for the undersizing group vs the oversizing group, P = 0.5].
The mean (SD) implantation depth for the SAPIEN
prostheses was 8.4% (11.6%) of prosthesis height below the
annulus [9% (10%) vs j10% (15.6%) for the undersizing
group vs the oversizing group, P = 0.3].
Outcome
Mortality rate within 30 days after implantation was
4.9%, 6-month mortality was 7.3%, and 1- and 2-year mortality
was 8.5%. No patient experienced stroke, 15 patients (18.5%)
required a new PM, and 10 patients (12.3%) had relevant
paravalvular regurgitation (grade 9 1+).
Retrospective Planning
Retrospective planning resulted in 243 plans. Time needed
for the retrospective planning varied between 2 and 15 minutes.
A learning curve could be seen for the participants. In seven
cases (9%), a smaller prosthesis and in 20 cases (24%), a larger
FIGURE 4. Distribution of new PM implantation in the equal-size, undersizing, and oversizing groups. A, The number of patients in
each group. B, The percentage of new PM implantations in each group. PM, pacemaker.
FIGURE 5. Distribution of paravalvular leakage of more than grade 2 in the equal-size, undersizing, and oversizing groups. A, The
number of patients with relevant paravalvular leak in each group. B, The percentage of relevant paravalvular leak in each group.
AI 0-2, no to mild paravalvular leak; AI 3-4, moderate to severe paravalvular leak. AI, aortic insufﬁciency.
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prosthesis would have been chosen by the participants. Results
are documented in Table 3.
The rate of new PM implantations was 18% in the total
patient cohort. In the oversizing patient cohort, the rate of new
PM implantations was much higher than in the undersizing
group (85% vs 10%, P = 0.001). In the equal-size group, the
rate of new PM implantations was 13% (Fig. 4). Sixty percent
of the patients with new PM implantation had a CoreValve.
The rate of relevant paravalvular leakage was 12% in the
total cohort. In the undersizing group, 35% of the patients had
relevant paravalvular leakage, whereas in the oversizing group,
no relevant AI was seen (P = 0.1). In the group with equal
sizing, the rate of relevant paravalvular leakage was 5.6%
(Fig. 5). Moreover, almost all patients (85%) in the undersized
group showed at least mild paravalvular leakage after the
procedure. Patients in the oversizing group had no or mild
paravalvular AI in 57% of the cases (P = 0.3). In 46% of the
cases in which retrospective planning resulted in equal-size
choice, neither of these complications was observed.
Univariate logistic regression showed that preoperative
RBBB, left bundle branch hemiblock (LBHB), and the afﬁli-
ation to the sizing group were associated with the need for
postinterventional new PM implantation. The results are
summarized in Table 4. In the purposeful selection of covari-
ates, LBHB was excluded. The multivariate analysis showed
RBBB and the afﬁliation to the sizing group to be independent
predictors for postoperative new PM implantation (P = 0.006
and P = 0.004, respectively). The depth of implantation of
CoreValve prostheses was not associated with new PM im-
plantations. In contrast, the depth of implantation of SAPIEN
prostheses was associated with new PM implantation. The
patients with new PM implantations in the SAPIEN group had
signiﬁcantly higher implantations [10% (11%) below the an-
nulus vsj2% (12%) below the annulus, P = 0.01]. For relevant
paravalvular leakage, no signiﬁcant association with the tested
variables was found.
DISCUSSION
We used 3D TAVI prosthesis templates to investigate
the hypothesis that this tool might improve the planning of
TAVI procedures compared with conventional 2D MDCT
measurements.
Paravalvular regurgitation is seen more frequently after
TAVI than after surgical aortic valve replacement and is as-
sociated with increased late mortality.4 In addition, TAVI is
frequently associated with new conduction defects, which re-
sult in LV asynchrony and subsequent impairment of LV
function.14,15 Correct preoperative prosthesis selection is a
crucial part of a TAVI procedure to avoid these complications.
For presurgical evaluation of valve pathology, transtho-
racic and transesophageal echocardiography are the criterion
standards.16 For the planning of TAVI procedures, additional
information is necessary because direct visualization and sizing
of the valve are not possible. Echocardiographicmeasurement of
the annulus diameter was used when TAVI was ﬁrst introduced
but is a less precise option thanMDCTbecause the aortic annulus
often is oval and intraobserver variability is higher than with
MDCT.17 Today, commonly used measurements for decision
making with regard to prosthesis selection are different geo-
metric parameters of the aortic annulus and aortic root and the
grade and location of calciﬁcation in 2D MDCT images.18
To support TAVIplanning, an imaging system that uses 3D
templates of the Edwards SAPIEN valve and application of this
system to DynaCT images of a cohort of 31 patients were de-
scribed in previous works.6,7 In this study, atrioventricular block
and paravalvular leakage were observed in those patients where
retrospective planning would have proposed a different size of
prosthesis. A strong limitation of that study was the small
number of patients and the fact that only one physician par-
ticipated.Moreover, DynaCT is an intraoperative modality not
commonly used and has been shown to be inferior to preop-
erative CTwith regards to the accuracy of annulus dimension
measurements.19
In the present study, we used an advanced version of the
previously proposed planning system, with additional tem-
plates for the CoreValve. The study design was strengthened by
having three independent study participants to plan each of
the 81 data sets. The results showed that almost all patients
who required a new PM after the intervention were in the
oversizing group and almost all patients planned retrospec-
tively for a larger prosthesis showed at least mild paravalvular
leakage after the procedure. Furthermore, the rate of relevant
AI was higher in the undersizing group than in the oversizing or
equal-size group. None of these results reached statistical
TABLE 4. Results for the Univariate Logistic Regression of
Potential Risk Factors Leading to Postinterventional New
PM Implantation
Odds Ratio
95% Conﬁdence
Interval P
Sizing group 3.7 1.6Y8.6 0.002
RBBB before intervention 10.5 2.2Y51 0.004
Sex 1.3 0.4Y4.2 0.6
EuroSCORE 1 0.9Y1 0.2
Previous valve surgery 0 V 1
Previous CABG 0.2 0.03Y1.7 0.1
Coronary heart disease 0.9 0.3Y2.8 0.8
Previous myocardial
infarction
0.6 0.07Y5.3 0.6
Previous PCI 0.9 0.3Y2.9 0.8
LBBB before intervention 1.9 0.3Y11 0.5
LBHB before intervention 3.6 0.9Y15 0.08
Atrial ﬁbrillation 1.3 0.4Y4.9 0.6
Porcelain aorta 0 V 1
Oval annulus 1 0.3Y3.3 0.9
Transapical access 1.1 0.2Y5.9 0.9
Valve type 0.4 0.1Y1.4 0.2
Postdilatation 0 V 1
Deep implantation 1 0.3Y3.5 0.9
Noncoronary sinus
depth (CV)
1 0.8Y1.1 0.6
Left coronary
sinus depth (CV)
0.9 0.8Y1 0.2
Mean depth (CV) 0.9 0.8Y1.1 0.3
Mean depth (SAPIEN) 0.9 0.8Y1 0.03
CV, CoreValve; LBBB, left bundle branch block; LBHB, left bundle hemiblock; PCI,
PCI, percutaneous coronary intervention; RBBB, right bundle branch block.
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signiﬁcance. This is most probably attributable to the small
number of events that can be compared.
We are aware that it can only be an assumption that the
choice of a smaller size valve would not have led to paravalvular
leakage and, vice versa, that the choice of a larger prostheses
would have reduced the rate of new PM implantations. In
addition, the majority of patients who required new PM im-
plantation had received a CoreValve (66%). It is well-known
that the rate of new conductive tissue disorders necessitating
new PM is higher after CoreValve implantation than after
SAPIEN implantation.14,20
The mean depth of implantation of CoreValve prostheses
in this series is very low compared with that in recent se-
ries,20,21 but no association between implantation depth and
new PM implantation was found. Of course, this might be due
to small sample sizes within the groups. In addition, there was
no difference between the oversizing and undersizing patient
groups with regard to implantation depth.
The results of this study underline the importance of
planning tools. Different ways of planning a procedure can lead
to different results.22 They also indicate that 3D template-based
planning may be a good additional tool to prevent paravalvular
leakage and new PM implantation.
Several limitations apply. This study is retrospective in
character and only includes patients treated at one center. The
planning was performed in a clinical setting with real patient
data; nevertheless, the physicians knew that their planning
decisions would not affect patient treatment. Five participants
were involved in the original valve selection and implantation;
because more than 6 months lay between treatment and ret-
rospective planning for the study, the bias generated by that
involvement was regarded as negligible but cannot be ex-
cluded completely. Probably the main limitation of the study
concerns theCoreValve group: the average depth of implantation
is much deeper than the depth considered best practice today.
This reﬂects an early learning curve andmay have inﬂuenced the
outcomes of the study. One consequence could be the low pos-
itive predictive value of concordant sizing. In the equal-size
group, only approximately half of the patients were free from
either newPMimplantationor paravalvular leak. This also shows
that besides sizing other factors such as the implantation tech-
nique and anatomic factors (calciﬁcation, left ventricular outﬂow
tract geometry, aortic angulation) play a major role.
CONCLUSIONS
The use of 3D prosthesis templates for the planning of
TAVI procedures is feasible. The ability tovisually assess the ﬁt of
an implant with the individual patient’s anatomy helps physicians
in determining the optimal implant size and position and might
provide an additional tool to improveplanningofTAVIprocedures
so as to prevent paravalvular leakage and newPM implantation. A
more contemporary prospective randomized trial is needed to
overcome the limitations of this study and to clearly show the
positive impact of 3D template-based procedure planning.
ACKNOWLEDGMENTS
The authors thank the following colleagues for their
contribution to this study as participants: Mani Arsalan, MD,
Johannes Blumenstein, MD, Won-Keun Kim, MD, Arnaud Van
Linden, MD, from the Kerkhoff Klinikum Bad Nauheim, Bad
Nauheim, Germany; Maximilian Emmert, MD, PhD, Christian
Felix, MD, He´ctor Rodriguez Cetina Biefer, MD, Lukas Altwegg,
MD, from the University Hospital Zurich, Zurich, Switzerland;
and Jacques Scherman, from the Christian Barnard Divi-
sion of Cardiothoracic Surgery, Groote Schuur Hospital,
Cape Town, South Africa. The authors also thank Maurizio
Taramasso for the statistical advice and Anne Gale for the
editorial assistance.
REFERENCES
1. Toggweiler S, Humphries KH, Lee M, et alR 5-year outcome after
transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;61:
413Y419.
2. Gurvitch R, Webb JG, Yuan R, et alR Aortic annulus diameter determi-
nation by multidetector computed tomography: reproducibility, applica-
bility, and implications for transcatheter aortic valve implantation. JACC
Cardiovasc Interv. 2011;4:1235Y1245.
3. Achenbach S, DelgadoV, Hausleiter J, Schoenhagen P,Min JK, Leipsic JA.
SCCT expert consensus document on computed tomography imaging
before transcatheter aortic valve implantation (TAVI)/transcatheter aortic
valve replacement (TAVR). J Cardiovasc Comput Tomogr. 2012;6:366Y380.
4. Buzzatti N, Maisano F, Latib A, et alR Computed tomography-based
evaluation of aortic annulus, prosthesis size and impact on early residual
aortic regurgitation after transcatheter aortic valve implantation. Eur J
Cardiothorac Surg. 2013;43:43Y50.
5. Kodali SK, Williams MR, Smith CR, et alR Two-year outcomes after
transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;
366:1686Y1695.
6. Gessat M, Merk DR, Falk V, et alR System for Transapical Aortic Valve
Implantation. Proceedings of SPIE Medical Imaging. 2009;7261:E1YE12.
7. Jacobs S, Gessat M, Walther T, Falk V. Three-dimensional template-based
planning for transapical aortic valve implantation. J Thorac Cardiovasc
Surg. 2011;141:1541Y1543.
8. Epstein AE, DiMarco JP, Ellenbogen KA, et alR 2012 ACCF/AHA/HRS
focused update incorporated into the ACCF/AHA/HRS 2008 guidelines
for device-based therapy of cardiac rhythm abnormalities: a report of the
American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation.
2013;127:e283Ye352.
9. Unbehaun A, Pasic M, Dreysse S, et alR Transapical aortic valve im-
plantation: incidence and predictors of paravalvular leakage and
transvalvular regurgitation in a series of 358 patients. J Am Coll Cardiol.
2012;59:211Y221.
10. Ledwoch J, Franke J, Gerckens U, et al; German Transcatheter Aortic Valve
Interventions Registry Investigators. Incidence and predictors of permanent
pacemaker implantation following transcatheter aortic valve implantation:
analysis from the German transcatheter aortic valve interventions registry.
Catheter Cardiovasc Interv. 2013;82:E569YE577.
11. Erkapic D, De Rosa S, Kelava A, et alR Risk for permanent pacemaker after
transcatheter aortic valve implantation: a comprehensive analysis of the
literature. J Cardiovasc Electrophysiol. 2012;23:391Y397.
12. Saia F, Lemos PA, Bordoni B, et alR Transcatheter aortic valve implantation
with a self-expanding nitinol bioprosthesis: prediction of the need for
permanent pacemaker using simple baseline and procedural characteris-
tics. Catheter Cardiovasc Interv. 2012;79:712Y719.
13. Nijhoff F, Agostoni P, Samim M, et alR Optimisation of transcatheter aortic
balloon-expandable valve deployment: the two-step inﬂation technique.
EuroIntervention. 2013;9:555Y563.
14. Urena M, Webb JG, Tamburino C, et alR Permanent pacemaker implan-
tation after transcatheter aortic valve implantation: impact on late clinical
outcomes and left ventricular function. Circulation. 2014;129:1233Y1243.
15. Hoffmann R, Herpertz R, Lotﬁpour S, et alR Impact of a new conduction
defect after transcatheter aortic valve implantation on left ventricular
function. JACC Cardiovasc Interv. 2012;5:1257Y1263.
Innovations & Volume 10, Number 5, September/October 2015 Simulated Prosthesis Overlay for TAVI Planning
Copyright * 2015 by the International Society for Minimally Invasive Cardiothoracic Surgery 321
Copyright © 2015 by the International Society for Minimally Invasive Cardiothoracic Surgery. Unauthorized reproduction of this article is prohibited.
16. Joint Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology (ESC), European Association for Cardio-
Thoracic Surgery (EACTS), Vahanian A, Alﬁeri O, Andreotti F, et alR
Guidelines on the management of valvular heart disease (version 2012).
Eur Heart J. 2012;33:2451Y2496.
17. Jabbour A, Ismail TF,Moat N, et alRMultimodality imaging in transcatheter
aortic valve implantation and post-procedural aortic regurgitation: com-
parison among cardiovascular magnetic resonance, cardiac computed to-
mography, and echocardiography. J Am Coll Cardiol. 2011;58:2165Y2173.
18. Tzikas A, Schultz CJ, Piazza N, et alR Assessment of the aortic annulus by
multislice computed tomography, contrast aortography, and trans-thoracic
echocardiography in patients referred for transcatheter aortic valve im-
plantation. Catheter Cardiovasc Interv. 2011;77:868Y875.
19. Lehmkuhl LH, von Aspern K, Foldyna B, et alR Comparison of aortic root
measurements in patients undergoing transapical aortic valve implantation
(TA-AVI) using three-dimensional rotational angiography (3D-RA) and
multislice computed tomography (MSCT): differences and variability. Int J
Cardiovasc Imaging. 2013;29:417Y424.
20. Khawaja MZ, Rajani R, Cook A, et alR Permanent pacemaker insertion
after CoreValve transcatheter aortic valve implantation: incidence and
contributing factors (the UK CoreValve Collaborative). Circulation. 2011;
123:951Y960.
21. Tchetche D, Modine T, Farah B, et alR Update on the need for a perma-
nent pacemaker after transcatheter aortic valve implantation using the
CoreValve\ Accutraki system. EuroIntervention. 2012;8:556Y562.
22. Kempfert J, Van Linden A, Lehmkuhl L, et alR Aortic annulus sizing:
echocardiographic versus computed tomography derived measurements in
comparison with direct surgical sizing. Eur J Cardiothorac Surg. 2012;
42:627Y633.
CLINICAL PERSPECTIVE
This is an excellent report describing a planning tool for transcatheter aortic valve implantation (TAVI) using a three-
dimensional model of the aortic root created from a data set obtained by preoperative multidimensional computer tomography.
The authors looked at 81 consecutive patients and retrospectively used this tool to plan the TAVI procedure. They compared the
prosthesis sizing obtained with this planning tool to the prosthesis size used in the actually performed procedure. In the group of
patients in which there was actual oversizing (retrospective planning predicted a smaller prosthesis), 85% of the patients had new
pacemaker implantation. In the patients in which there was undersizing in the actual procedure, the majority had at least a mild
paravalvular leak. In the 46% of patients in which the prosthesis usedmatched that recommended by the planning tool, neither of
these complications were observed.
This type of simulation is an important advance, and planning tools such as this one have the potential to greatly reﬁne
implantation techniques. This group is to be congratulated for their beautiful work. The ability to visually assess the ﬁt of an
implant with the actual patient’s anatomy could limit procedural complications. Future prospective studies from this group and
others will continue to deﬁne the role of simulated procedural planning in improving TAVI outcomes.
Su¨ndermann et al Innovations & Volume 10, Number 5, September/October 2015
322 Copyright * 2015 by the International Society for Minimally Invasive Cardiothoracic Surgery
Copyright © 2015 by the International Society for Minimally Invasive Cardiothoracic Surgery. Unauthorized reproduction of this article is prohibited.
